Biotechnology
RMS Announces 25% Wisconsin Tax Credit For Investing In Prospective Cure For Diabetes
Share
Madison, Wisconsin, July 29, 2025 (GLOBE NEWSWIRE) -- The Wisconsin Economic Development Corporation (WEDC) has approved a 25% tax credit for investors in a groundbreaking diabetes cure being developed by Wisconsin-based biotechnology company Regenerative Medical Solutions, Inc. (RMS). This tax incentive encourages visionary investors to join RMS in revolutionizing diabetes treatment with the opportunity to receive an exceptional potential return on their investment.
RMS is pioneering a cure for diabetes by converting human-induced pluripotent stem cells (iPSCs) into islet-like clusters (ILCs). These ILCs will be transplanted to restore insulin production and regulate blood glucose levels, with applications in both Type 1 and Type 2 diabetes. This approach will eliminate reliance on organ donors and the need for heavy immunosuppressive drugs, which often have severe side effects.
CEO Anthony Kolton expressed his excitement about the progress achieved through this initiative by stating, “The development of a working diabetes cure brings genuine hope for all diabetes patients because it represents a life-changing development for everyone with the disease. For Wisconsin investors, this is a chance to impact public health and receive a 25% income tax credit for their support. For every dollar that a Wisconsin investor invests in RMS, the investor will receive 25 cents in the form of a tax credit.”
With millions of people living with diabetes and current solutions like insulin and organ transplantation failing to meet patient needs, RMS’s innovative therapy offers a promising alternative.
RMS invites interested investors to support its mission and play an integral role in bringing this pioneering diabetes cure to market.
Interested investors may contact info@regenmedsolutions.com to learn more about the 25% WEDC tax credit and request a prospectus for investing, or visit the RMS website to learn more: https://www.regenmedsolutions.com/investors/
About Regenerative Medical Solutions
Regenerative Medical Solutions, Inc. (RMS), is a privately held biotechnology company focused on regenerative medicine and stem cell therapy for diabetes. Leveraging over 25 years of research, RMS is pioneering a potential cure for diabetes using human-induced pluripotent stem cell (iPSC) therapy. Our groundbreaking approach aims to offer a safe and effective solution for type 1 and type 2 diabetes and eliminates the need for anti-rejection drugs in diabetes treatment. RMS is committed to developing ethical, non-embryonic stem cell therapies to provide a lasting diabetes cure. This innovative biotech company operates in Madison, Wisconsin.
CONTACT: Regenerative Medical Solutions 505 S Rosa Road, Suite 26 Madison WI 53719 United States 312 725 6450 https://www.regenmedsolutions.com/
Frequently Asked Questions
What is Regenerative Medical Solutions developing?
Regenerative Medical Solutions is pioneering a cure for diabetes by converting human-induced pluripotent stem cells (iPSCs) into islet-like clusters (ILCs) for transplantation.
What is the potential benefit of this therapy?
This therapy aims to restore insulin production and regulate blood glucose levels, eliminating reliance on organ donors and immunosuppressive drugs.
What incentive is offered to Wisconsin investors?
The Wisconsin Economic Development Corporation (WEDC) has approved a 25% tax credit for investors in Regenerative Medical Solutions.
First published on Wed, Jul 30, 2025
Liked what you read? That’s only the tip of the tech iceberg!
Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!
Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.
Dive into TechDogs' treasure trove today and Know Your World of technology like never before!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending GlobeNewswire
Apiiro Redefines Design-Phase Security With AI Threat Modeling Built For The AI Coding Agent Erapreventing Risks Before Code Exists
Brandfuel.Ai And Hairball.Io Announce Partnership To Deliver The First AI-Native Product Publishing Workflow For Netsuite Merchants
Cycode Unveils Agentic Development Security Platform
ESET Launches Cloud Workload Protection And AI Enhancements For ESET PROTECT Customers
ESET Presents Six Sessions At RSAC 2026 To Advance Cyber Resilience
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion